LETIM Robustly Predicts Immune Checkpoint Blockade Efficacy for Liver Cancer Patients Using Multiple Immune‐Related Genesets

Documenti analoghi

• Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
  di: Takanori Ito, et al.
  Pubblicazione: (2025)
• The Impact of Hepatitis B Virus on the Tumor Microenvironment of Hepatocellular Carcinoma and Therapeutic Strategies
  di: Ximing Li, et al.
  Pubblicazione: (2026)
• Comments on “Immune Checkpoint Inhibitor‐Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: A Systematic Review and meta‐Analysis”
  di: Zheng Zhang, et al.
  Pubblicazione: (2026)
• Tocilizumab Mitigates Immune Checkpoint Inhibitor–Induced Colitis and Inhibits Tumor Growth by Targeting the IL‐6‐JAK2‐STAT3 Signaling Pathway
  di: Yanxin Chen, et al.
  Pubblicazione: (2026)
• Characterization of NK Cells Using Single‐Cell RNA Sequencing in Patients With Acute‐On‐Chronic Liver Failure
  di: Ninghui Zhao, et al.
  Pubblicazione: (2025)